{
  "id": 12451325,
  "title": "Switching from GLP-1 Injections to Wegovy Pill Shows Additional Weight Loss of 4.1%",
  "url": "https://urgent.news/2026/10/06/switching-from-glp-1-injections-to-wegovy-pill-shows-additional",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T17:38:18.000Z",
  "source": {
    "name": "Healthline News",
    "slug": "healthline-news",
    "url": "https://www.healthline.com/health-news/switching-from-glp-1-injections-wegovy-pill-greater-weight-loss"
  },
  "original_language": "en",
  "account": "A new study presented at the European Association for the Study of Diabetes meeting in Milan found that people who switch from GLP-1 injections to Wegovy pills can lose an additional 4.1% of their body weight over three months. Among 194 adults with overweight or obesity, about two-fifths (40.7%) lost at least 5% of their body weight after three months. The overall proportion of participants with obesity decreased by 21.6 percentage points, from 87.1% at the beginning of the study to 65.5% after three months. The study highlights the real-world effectiveness of oral semaglutide (Wegovy) as a weight loss treatment, though it does not prove causation. Experts suggest considering factors like treatment efficacy, side effects, and personal preferences when deciding between pills and injections.",
  "summary": "Recent research shows people who switch to the Wegovy pill from a GLP-1 injection can lose additional weight. PixelsEffect · E+/Getty People with overweight or obesity who switched from an injectable GLP-1 weight loss medication to the Wegovy (semaglutide) pill lost an average of 4.1% of their body weight over 3 months. After 3 months, about 2 in 5 participants had lost at least 5% of their body…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}